Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Will Bausch Health Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Bausch Health.

BHC : 27.73 (-1.70%)
Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed

Aerie (AERI) posts a wider-than-expected Q3 loss and lowers guidance.

PFE : 37.05 (-1.62%)
AGN : 184.96 (-0.14%)
AERI : 17.85 (-5.41%)
BHC : 27.73 (-1.70%)
Is Bausch Health (BHC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

BHC : 27.73 (-1.70%)
Innovative Biotechs Look to Tackle Ocular Ailments

Visual impairment is one of the most common health conditions that negatively impact millions of Americans' physical and mental health. Visual impairment is defined as 20/40 vision, or worse, in the better...

QBIO : 1.6200 (+343.84%)
JNJ : 135.94 (+0.83%)
AGN : 184.96 (-0.14%)
BHC : 27.73 (-1.70%)
AERI : 17.85 (-5.41%)
Bausch (BHC) Moves to Buy: Rationale Behind the Upgrade

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BHC : 27.73 (-1.70%)
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance

Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.

LCI : 8.91 (-1.00%)
PTLA : 29.03 (-0.48%)
FGEN : 37.79 (+0.37%)
BHC : 27.73 (-1.70%)
Bausch Health (BHC) Q3 Earnings and Revenues Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of 12.26% and 2.54%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BHC : 27.73 (-1.70%)
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BHC : 27.73 (-1.70%)
Implied Volatility Surging for Bausch Health (BHC) Stock Options

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

BHC : 27.73 (-1.70%)
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

NVS : 90.53 (+0.14%)
INCY : 88.90 (+1.09%)
TEVA : 10.42 (+1.26%)
BHC : 27.73 (-1.70%)
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

PFE : 37.05 (-1.62%)
FGEN : 37.79 (+0.37%)
AERI : 17.85 (-5.41%)
BHC : 27.73 (-1.70%)
Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

FOMX : 3.41 (+0.29%)
EVOK : 1.30 (-2.26%)
RDY : 39.88 (+3.67%)
BHC : 27.73 (-1.70%)
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela....

AGN : 184.96 (-0.14%)
IRWD : 11.80 (+2.61%)
ARDX : 6.85 (-3.25%)
BHC : 27.73 (-1.70%)
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

AGN : 184.96 (-0.14%)
IRWD : 11.80 (+2.61%)
ARDX : 6.85 (-3.25%)
BHC : 27.73 (-1.70%)
Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

Is (BHC) Outperforming Other Medical Stocks This Year?

BHC : 27.73 (-1.70%)
Is Bausch Health Cos (BHC) a Good Value Investor Pick?

Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

BHC : 27.73 (-1.70%)
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

PFE : 37.05 (-1.62%)
RHHBY : 38.1700 (-0.34%)
AERI : 17.85 (-5.41%)
BHC : 27.73 (-1.70%)
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

GALT : 3.03 (-2.26%)
PTLA : 29.03 (-0.48%)
BHC : 27.73 (-1.70%)
ETON : 5.94 (+1.11%)
Bausch Health (BHC) Misses Q2 Earnings and Revenue Estimates

Bausch (BHC) delivered earnings and revenue surprises of -2.83% and -0.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

BHC : 27.73 (-1.70%)
What's in the Cards for Bausch Health (BHC) in Q2 Earnings?

Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q2 results on Aug 6.

RIGL : 2.35 (+3.52%)
JAZZ : 140.65 (+1.26%)
ETON : 5.94 (+1.11%)
BHC : 27.73 (-1.70%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +2.57 , AIZ +0.18 , SBAC +0.76 , SO +0.57 , WELL -0.26
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar